Loading...
*  PARENTAL RIGHTS II: Seasonal Influenza Vaccine Safety:Things We thought You Need To Know
Seasonal influenza vaccination is the most important way of preventing seasonal influenza virus infections and potentially severe complications, including death. Seasonal influenza vaccination reduces the likelihood of becoming ill with influenza or transmitting influenza to others.•Seasonal influenza vaccines do not contain the 2009 H1N1 strain and are not expected to provide significant cross-protection against pandemic (H1N1) 2009 influenzaInfluenza A (H1N1) 2009 monovalent vaccines to prevent the 2009 H1N1 virus have been licensed; initial doses of licensed vaccine ...
  http://strengthfromtears.blogspot.com/2010/03/seasonal-influenza-vaccine-safety.html
*  Influenza Vaccination Coverage Among Children Aged 6--59 Months --- Six Immunization Information System Sentinel Sites,...
In June 2006, the Advisory Committee on Immunization Practices (ACIP) expanded its 2004 recommendation for routine influenza vaccination of children aged 6--23 months to include children aged 24--59 months. The 2006 ACIP recommendations also reemphasized that previously unvaccinated children aged ,9 years should receive 2 doses of influenza vaccine administered at least 1 month apart to be fully vaccinated (1). In 2007, using data from six immunization information system (IIS)* sentinel sites, CDC conducted the first assessment of influenza vaccination coverage among children aged 6--59 months during the 2006--07 influenza season. The findings demonstrated that, at all six sites, ,30% of children aged 6--23 months and ,20% of children aged 24--59 months were fully vaccinated. Vaccination coverage data from ...
  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5637a3.htm
*  Prevention and Control of Seasonal Influenza with Vaccines, 2017-18 | Seasonal Influenza (Flu) | CDC
This report updates the 2016-17 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines (MMWR Recomm Rep 2016;65[No. RR-5]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used.. For the 2017-18 season, quadrivalent and trivalent influenza vaccines will be available. Inactivated influenza vaccines (IIVs) will be available in trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in trivalent (RIV3) and quadrivalent (RIV4) formulations. Live attenuated ...
  https://www.cdc.gov/flu/professionals/acip/index.htm
*  Prevention and Control of Influenza with Vaccines: Interim Recommendations of the Advisory Committee on Immunization Practices ...
This report summarizes recommendations approved on February 21, 2013, by the Advisory Committee on Immunization Practices (ACIP) for the use of influenza vaccines. An expanded 2013 ACIP influenza vaccination recommendation statement is scheduled to be published in MMWR Recommendations and Reports before the start of the 2013-14 influenza season. Providers should consult the expanded 2013 ACIP influenza vaccination statement for complete and updated information. Vaccine Recommendations Routine annual influenza vaccination is recommended for all persons aged ≥6 months. Immunization providers should consult Food and Drug Administration-approved prescribing information for 2013-14 influenza ...
  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a3.htm?s_cid=mm6218a3_e
*  Influenza Vaccination Coverage Among Children Aged 6--23 Months --- United States, 2006--07 Influenza Season
Please note: An erratum has been published for this article. To view the erratum, please click here. Children aged ,5 years have more influenza-related medical-care visits compared with older children, and those aged ,2 years are at the greatest risk for influenza-related hospitalizations (1). In 2002, the Advisory Committee on Immunization Practices (ACIP) encouraged annual influenza vaccination of children aged 6--23 months and then, in 2004, recommended vaccination for this group (2). Two doses, spaced at least 4 weeks apart, are recommended to fully vaccinate children aged ,9 years who are receiving influenza vaccination for the first time. This report, based on data from the 2007 National Immunization Survey (NIS), provides an assessment of influenza ...
  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5738a2.htm
*  Early Estimates of Seasonal Influenza Vaccine Effectiveness - United States, January 2013
The early onset of the 2012-13 influenza season offered an opportunity to provide an early VE estimate. Overall, the estimate suggests that the 2012-13 influenza vaccine has moderate effectiveness against circulating influenza viruses, similar to a summary VE estimate from a meta-analysis of randomized controlled clinical trial data (2). Influenza vaccination, even with moderate effectiveness, has been shown to reduce illness, antibiotic use, doctor visits, time lost from work, hospitalizations, and deaths (6). Results for the 2012-13 season indicate that vaccination has reduced the risk for influenza-associated medical visits by approximately 60%, demonstrating the benefits of influenza vaccination during ...
  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm62e0111a1.htm?s_cid=mm62e0111a1_
*  Europe Influenza Vaccine Market & Forecast (23 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine...
5 Countries of Europe Collectively Control more than 80 percent in the Europe Influenza Vaccine Market. Influenza virus is mostly activated in the winter season every year in the European region. Vaccination is the best way to prevent from Influenza virus. It is anticipated that Influenza vaccine market is near to US$ 1 Billion due to a large target population, strong public healthcare infrastructure, high per capita healthcare spending and influenza vaccination program in European countries. Our research report title "Europe Influenza Vaccine Market, Vaccinated Population (23 Countries Market Data) By (Child & Adult) & Forecast" cover the following points:. • ...
  http://www.southdakotachronicle.com/europe-influenza-vaccine-market-forecast-23-countries-market-vaccinated-population-data-by-pediatrics-adult-vaccine-brands-analysis.html
*  Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine...
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.. Get Free 10% Customization in this Report. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan ...
  http://www.iowanewsheadlines.com/story/119520/global-influenza-vaccine-market-forecast-30-countries-market-vaccinated-population-data-by-pediatrics-adult-vaccine-brands-analysis.html
*  Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine...
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.. Get Free 10% Customization in this Report. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan ...
  http://www.pennsylvania-magazine.com/story/123541/global-influenza-vaccine-market-forecast-30-countries-market-vaccinated-population-data-by-pediatrics-adult-vaccine-brands-analysis.html
*  Global Influenza Vaccine Market & Forecast (30 Countries Market & Vaccinated Population Data) By (Pediatrics & Adult) & Vaccine...
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period.. Get Free 10% Customization in this Report. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine Market Share was almost 4 times more than China and Japan ...
  http://www.saintpaulchronicle.com/story/123240/global-influenza-vaccine-market-forecast-30-countries-market-vaccinated-population-data-by-pediatrics-adult-vaccine-brands-analysis.html
*  Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects - Tabular View -...
The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of MF59-adjuvanted subunit seasonal influenza vaccine with respect to immunogenicity in subjects aged 65 years and older. The active comparator non-adjuvanted seasonal influenza vaccine is approved for use in this age group in the United States and will be used to provide a comparative assessment for immunogenicity and safety ...
  https://clinicaltrials.gov/ct2/show/record/NCT01162122
*  Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults - Full Text...
To determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on humoral antibody responses, measured by hemagglutinin inhibition assay (HAI), to each of three strains included in the seasonal non-adjuvanted trivalent influenza vaccine In this study we will use the following definitions to assess the humoral immune response to TIV: HAI titers ,1:10 = seronegative; HAI titers ≥1:10 = seropositive; HAI titers ≥1:40 = sero-protective; sero-response rate (primary outcome measure) will be defined as a titer of ≥1:40 in an individual with baseline titers of ,1:10, or ,4-fold increase of HAI titers if baseline titers were ≥1:10. Hemagglutination inhibition assays will be performed on serum as per recommended methods. Sera will be titrated against antigens from the influenza vaccine strains included in the 2013 seasonal TIV ...
  https://clinicaltrials.gov/ct2/show/study/NCT01811823?view=record
*  Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults - Tabular View ...
To determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on humoral antibody responses, measured by hemagglutinin inhibition assay (HAI), to each of three strains included in the seasonal non-adjuvanted trivalent influenza vaccine In this study we will use the following definitions to assess the humoral immune response to TIV: HAI titers ,1:10 = seronegative; HAI titers ≥1:10 = seropositive; HAI titers ≥1:40 = sero-protective; sero-response rate (primary outcome measure) will be defined as a titer of ≥1:40 in an individual with baseline titers of ,1:10, or ,4-fold increase of HAI titers if baseline titers were ≥1:10. Hemagglutination inhibition assays will be performed on serum as per recommended methods. Sera will be titrated against antigens from the influenza vaccine strains included in the 2013 seasonal TIV ...
  https://clinicaltrials.gov/ct2/show/record/NCT01811823?term=%22+February+18%2C++2013%22%3A%22+March+20%2C++2013%22%5BFIRST-RECEIVED-DATE%5DAND+HIV%5BCONDITION%5D
*  2017 Forecast - Influenza Vaccines Global Market, Industry Size, Share, Analysis and Opportunities to 2023. - QWTJ Live
Latest industry research report on Influenza Vaccines Market. Influenza is a type of seasonal or pandemic condition causing fever, coryza, cough, headache, and malaise. The severity of influenza symptoms varies across age groups and type of influenza. According to the World Health Organization (WHO), approximately, 3 to 5 million people are prone to seasonal epidemics, annually.. The growing number of ageing population and an increase in the frequency of seasonal influenza outbreak supplement the demand for influenza vaccines across the healthcare industry. Intellectual property rights are providing security to the patent holders, thereby, increases their market share. ...
  http://qwtjlive.com/2017/04/2017-forecast-influenza-vaccines-global-market-industry-size-share-analysis-opportunities-2023/37319/
*  Influenza Vaccination Coverage Among Children and Adults --- United States, 2008--09 Influenza Season
Before 2008, the Advisory Committee on Immunization Practices (ACIP) had recommended annual vaccination for influenza for persons aged ≥50 years, 18--49 years at higher risk for influenza complications, and 6 months--4 years (1). In 2008, ACIP expanded the recommendations to include all children aged 5--18 years, beginning with the 2008--09 season, if feasible, but no later than the 2009--10 season (2). This expansion added 26 million children and adolescents to groups recommended for routine influenza vaccination. To assess vaccination uptake among children and adults during the 2008--09 influenza season, CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) in 19 states, which represent 43% of the U.S. population. This report summarizes the results of the analysis, which indicated ...
  https://www.cdc.gov/MMWr/preview/mmwrhtml/mm5839a1.htm
*  AAP backs new ACIP recommendation on influenza vaccine - Wisconsin Chapter of the Academy of Pediatrics (WIAAP)
Health care providers should not use live attenuated influenza vaccine (LAIV) in the upcoming 2016-'17 season due to poor effectiveness, a Centers for Disease Control and Prevention (CDC) committee said Wednesday.. Academy leaders say they support the interim recommendation by the CDC's Advisory Committee on Immunization Practices (ACIP).. "We agree with ACIP's decision today to recommend health care providers and parents use only the inactivated vaccine for this influenza season," said AAP President Benard Dreyer, M.D., FAAP.. The AAP recommends children ages 6 months and older be immunized against influenza every year. Previously, the CDC and AAP had recommended either form of flu vaccine - the inactivated influenza vaccine (IIV) that is given by injection and is approved for all patients older than 6 ...
  http://www.wiaap.org/news/295413/National-AAP-backs-new-ACIP-recommendation-on-influenza-vaccine.htm
*  MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly - Full Text View - ClinicalTrials.gov
Many VA patients are at-risk for complications from influenza because of advanced age and underlying chronic diseases. A more effective influenza virus vaccine is needed in older patient populations and high antibody levels are correlated with protection. Vaccine dose-sparing to maximize the number of doses available is a public health goal. The combination of influenza vaccine antigens with an adjuvant could help improve the vaccine. This study will be a phase 1, 2 randomized, observer-blind, multi-center, clinical trial, in patients aged 65 years and older, evaluating the immunogenicity and safety of a water-in-oil emulsion adjuvant (MAS-1) combined with each of three reduced influenza hemagglutinin (HA) antigen dose levels of trivalent influenza virus ...
  https://clinicaltrials.gov/show/NCT01623232
*  AstraZeneca's FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) nasal-spray flu vaccine begins shipping for 2015-2016...
Nearly 15 million doses will be distributed in the US to help protect eligible individuals 2 to 49 years of age against influenza. AstraZeneca began shipping its first doses of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal), developed by MedImmune, our global biologics research and development arm, for the 2015-2016 flu season today. FluMist Quadrivalent, the first and only needle-free, nasal spray flu vaccine approved by the Food and Drug Administration, helps protect against four influenza strains contained in the vaccine: two influenza A strains and two influenza B lineages.1,2. A needle-free, nasal spray option for eligible individuals 2 to 49 years of age, FluMist Quadrivalent is administered as a mist ...
  https://www.astrazeneca-us.com/media/press-releases/2015/astrazenecas-flumist-quadrivalent-now-shipping-20150903.html
*  Studies Fail To Demonstrate Safety Or Effectiveness Of Influenza Vaccine In Children And Adults
... An independent analysis by the internationally renowned Cochrane Collaboration of worldwide influenza vaccine studies, published in the British Medical Journal on Oct. 28, concluded there is little scientific proof that inactivated influenza vaccine is safe and effective for children and adults. Citing the Cochrane Collaboration finding as well as methodological flaws in a child influenza vaccine study published Oct. 25 in the Journal of the American Medical Association (JAMA), the National Vaccine Information Center is calling on the Centers for Disease Control (CDC) to stop recommending annual flu shots for all infants and children until methodologically sound studies are conducted.. "There is a big gap between policies promoting annual influenza vaccinations for most children and adults and ...
  http://atlaschiro.com/studies-fail-to-demonstrate-safety-or-effectiveness-of-influenza-vaccine-in-children-and-adults/
*  Licensure of a High-Dose Inactivated Influenza Vaccine for Persons Aged ≥65 Years (Fluzone High-Dose) and Guidance for Use ---...
Persons aged ≥65 years are at greater risk for hospitalization and death from seasonal influenza compared with other age groups (1,2), and they respond to vaccination with lower antibody titers to influenza hemagglutinin (an established correlate of protection against influenza) compared with younger adults (3). On December 23, 2009, the Food and Drug Administration (FDA) licensed an injectable inactivated trivalent influenza vaccine (Fluzone High-Dose, Sanofi-Pasteur) that contains an increased amount of influenza virus hemagglutinin antigen compared with other inactivated influenza vaccines such as Fluzone. Fluzone High-Dose is licensed as a single dose for use among persons aged ≥65 years ...
  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5916a2.htm?s_cid=mm5916a2_e
*  TravelSafe Clinic - Travel Health, Yellow Fever Disease & Vaccination.: Examining Common Arguments Against Influenza Vaccination
Influenza, however, is unique among respiratory viral pathogens in that another effective intervention to prevent transmission exists: vaccination. Annual influenza vaccination has been available in the United States since 1945 and has been recommended for persons at high risk of influenza complications since 1960. Unlike many pathogens, the predominant circulating influenza strains vary from year to year, affecting the intensity and severity of the influenza season as well as vaccine effectiveness. According to a recent systematic review and meta-analysis of influenza vaccine protection, there was 59% effectiveness of the trivalent ...
  http://yellowfevervaccine.blogspot.com/2013/02/examining-common-arguments-against.html
*  Notice to Readers: Expansion of Eligibility for Influenza Vaccine Through the Vaccines for Children Program
On June 20, 2002, the Advisory Committee on Immunization Practices (ACIP) adopted a resolution expanding the group of children eligible for influenza vaccine coverage under the Vaccines for Children (VFC) program. The resolution extends VFC coverage for influenza vaccine to all VFC-eligible children aged 6--23 months and VFC-eligible children aged 2--18 years who are household contacts of children aged ,2 years. The resolution becomes effective on March 1, 2003, for vaccine to be administered during the 2003--04 influenza vaccination season and subsequent seasons. ACIP is expanding VFC influenza coverage because children aged ,23 months are at substantially increased risk for influenza-related hospitalizations. For the upcoming 2002--03 ...
  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5138a7.htm
*  Sarasota for Vaccination Choice (SVC): Live Attenuated Swine Influenza Vaccine for Children Safety in Question
Because classical reassortment methods (see [1]) for producing influenza vaccine are time-consuming and cumbersome, a new , more efficient and faster "reverse genetics" method was devised that assembles RNA virus from the genes on DNA plasmids. For vaccine production, eight plasmids -containing the HA and NA genes from pathogenic influenza strains plus six genes from a non pathogenic master strain - along with additional plasmids encoding proteins necessary for replication and transcription, are transfected into cell lines [9]. Virus can then be harvested from these cells for the production of inactivated or live attenuated vaccine. ` Live attenuated influenza vaccine (LAIV) was originally derived by cold adaptation of an influenza type A strain by serial passage at sequentially lower ...
  http://svcsrq.blogspot.com/2009/09/live-attenuated-swine-influenza-vaccine.html
*  Bharat Book Bureau: PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis
M2 PressWIRE Via Acquire Media NewsEdge) Summary 'PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis'. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the ...
  http://it.tmcnet.com/news/2014/08/20/7978915.htm
*  Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine : a Phase I...
Live attenuated influenza vaccine (LAIV) offers the promise of inducing a variety of immune responses thereby conferring protection to circulating field strains. LAIVs are based on cold adapted and temperature sensitive phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of seasonal influenza strains. Two types of MDV lineages have been described, the Ann Arbor lineages and the A/Leningrad/17 and B/USSR/60 lineages. Here the safety and immunogenicity of a Madin Darby Canine Kidney - cell culture based, intranasal LAW derived from A/Leningrad/17 and B/USSR, was evaluated in healthy influenza non-naive volunteers 18-50 years of age. In a double-blind, randomized, placebo-controlled design, single escalating doses of 1 x 10(5),1 x 10(6), or 1 x 10(7) tissue culture infectious dose 50% (TCID50) of ...
  https://repository.uantwerpen.be/link/irua/119879